Literature DB >> 28638740

Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

Qian Zhu1,2, Mu-Yan Cai1,3, Chang-Long Chen1,2, Hao Hu4, Huan-Xin Lin1,5, Min Li1,3, De-Sheng Weng1,2, Jing-Jing Zhao1,2, Ling Guo1,6, Jian-Chuan Xia1,2.   

Abstract

Programmed death ligand 1 (PD-L1) expression represents a mechanism of immune escape by inhibiting T cell immunity. This study systematically evaluated the expression of PD-L1, spatial distribution of CD3+ immune cells and the relationship of both factors to survival in nasopharyngeal carcinoma (NPC) patients. A total of 209 NPC patients treated between 1991 and 2000 were included. Pairs of TMAs were immunohistochemically stained with PD-L1 and CD3. Survival analysis was evaluated according to PD-L1 status and the spatial distribution of CD3+ immune cells in the primary lesion microenvironment. PD-L1 staining was observed on tumor cells and tumor-infiltrating immune cells (TILs); however, PD-L1-positive immune cells were more common (98/209) than PD-L1-positive tumor cells (68/209). Limited numbers of intra-tumoral CD3+ T cells (median number: 20) were detected. Patients with higher CD3+ T cell infiltration, both intratumorally and peritumorally, had higher PD-L1 expression on tumor cells (both p < 0.001) and immune cells (p = 0.002 and p < 0.001, respectively). Increasing intratumoral CD3 infiltration was correlated with increased overall survival (OS) (p = 0.008) and disease-free survival (DFS) (p = 0.003). Nevertheless, patients with low levels of peritumoral TILs showed superior OS (p = 0.557) and DFS to those with higher levels of peritumoral TILs (p = 0.671). Moreover, type classification based on intratumoral CD3 infiltration and tumor cell PD-L1 expression was an independent prognostic factor for NPC patients. PD-L1 expression on tumor cells is a favorable prognosis factor in NPC patients with pre-existing intratumor-infiltrating lymphocytes.

Entities:  

Keywords:  Nasopharyngeal carcinoma; PD-L1; prognosis; tumor-infiltrating lymphocytes

Year:  2017        PMID: 28638740      PMCID: PMC5467992          DOI: 10.1080/2162402X.2017.1312240

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  42 in total

Review 1.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

2.  Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.

Authors:  Yuichiro Ohigashi; Masayuki Sho; Yukishige Yamada; Yoshikazu Tsurui; Kaoru Hamada; Naoya Ikeda; Takashi Mizuno; Ryo Yoriki; Hisanori Kashizuka; Katsunari Yane; Fumihiko Tsushima; Noriko Otsuki; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 3.  The battle against nasopharyngeal cancer.

Authors:  Anne W M Lee; W T Ng; Y H Chan; Henry Sze; Connie Chan; T H Lam
Journal:  Radiother Oncol       Date:  2012-08-30       Impact factor: 6.280

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Release of surface-expressed lactoferrin from polymorphonuclear neutrophils after contact with CD4+ T cells and its modulation on Th1/Th2 cytokine production.

Authors:  Ko-Jen Li; Ming-Chi Lu; Song-Chou Hsieh; Cheng-Han Wu; Hsin-Su Yu; Chang-Youh Tsai; Chia-Li Yu
Journal:  J Leukoc Biol       Date:  2006-06-12       Impact factor: 4.962

6.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.

Authors:  Elena Fountzilas; Vassiliki Kotoula; Nikolaos Angouridakis; Ilias Karasmanis; Ralph M Wirtz; Anastasia G Eleftheraki; Elke Veltrup; Konstantinos Markou; Angelos Nikolaou; Dimitrios Pectasides; George Fountzilas
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  30 in total

1.  Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.

Authors:  E Muraro; E Vaccher; C Furlan; E Fratta; G Fanetti; D A Fae'; D Martorelli; M Cangemi; J Polesel; F Navarria; C Gobitti; E Comaro; C Scaini; C Pratesi; S Zanussi; V Lupato; G Grando; V Giacomarra; S Sulfaro; L Barzan; R Dolcetti; A Steffan; V Canzonieri; G Franchin
Journal:  Pathol Oncol Res       Date:  2020-06-21       Impact factor: 3.201

Review 2.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

3.  Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area.

Authors:  J Boustani; A Ruffier; A Moya-Plana; Y Tao; F Nguyen; C Even; C Berthold; O Casiraghi; S Temam; P Blanchard
Journal:  Strahlenther Onkol       Date:  2020-06-08       Impact factor: 3.621

Review 4.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12

5.  Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.

Authors:  Fumihiko Sato; Takeharu Ono; Akihiko Kawahara; Toshihiko Kawaguchi; Hisaichiro Tanaka; Kazuhide Shimamatsu; Tatsuyuki Kakuma; Jun Akiba; Hirohito Umeno; Hirohisa Yano
Journal:  J Clin Pathol       Date:  2019-05-21       Impact factor: 3.411

6.  Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma.

Authors:  Sai-Lan Liu; Li-Juan Bian; Ze-Xian Liu; Qiu-Yan Chen; Xue-Song Sun; Rui Sun; Dong-Hua Luo; Xiao-Yun Li; Bei-Bei Xiao; Jin-Jie Yan; Zi-Jian Lu; Shu-Mei Yan; Li Yuan; Lin-Quan Tang; Jian-Ming Li; Hai-Qiang Mai
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

7.  Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Authors:  Brigette B Y Ma; Wan-Teck Lim; Boon-Cher Goh; Edwin P Hui; Kwok-Wai Lo; Adam Pettinger; Nathan R Foster; Jonathan W Riess; Mark Agulnik; Alex Y C Chang; Akhil Chopra; Julie A Kish; Christine H Chung; Douglas R Adkins; Kevin J Cullen; Barbara J Gitlitz; Dean W Lim; Ka-Fai To; K C Allen Chan; Y M Dennis Lo; Ann D King; Charles Erlichman; Jun Yin; Brian A Costello; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 50.717

8.  CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.

Authors:  Nasser Al-Rajhi; Hussein Soudy; Shoaib A Ahmed; Tusneem Elhassan; Shamayel F Mohammed; Hatim A Khoja; Hazem Ghebeh
Journal:  BMC Cancer       Date:  2020-03-21       Impact factor: 4.430

Review 9.  Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.

Authors:  Ramon Yarza; Mateo Bover; Maria Teresa Agulló-Ortuño; Lara Carmen Iglesias-Docampo
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

10.  Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.

Authors:  Birhanu Aberha Berele; Yuxiang Cai; Guifang Yang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.